GlassScriptPhysician profile
Judith L Bateman
NPI 1356431381
$1,062.24
in general payments reported to CMS, 2019-2025
12 companies · $210 in 2025
The $210 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $80.51 · 2022: $46.40 · 2023: $26.00 · 2024: $425 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $521 · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $521.28 |
| Education | $139.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $246.58 | 2024 | Breztri, Airsupra |
| Janssen Biotech, INC. | $180.22 | 2020-2025 | Tremfya |
| Amgen INC. | $155.66 | 2020-2024 | |
| Pfizer INC. | $150.01 | 2019 | |
| Novo Nordisk INC | $124.98 | 2025 | |
| Horizon Therapeutics Plc | $73.55 | 2019-2023 | |
| Pacira Therapeutics, INC. | $31.59 | 2019 | |
| Genentech USA, INC. | $27.76 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $22.01 | 2020 | |
| Aurinia Pharma U.S., INC. | $19.69 | 2022 | |
| Glaxosmithkline, LLC. | $15.52 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Bateman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.